Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
about
Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
P2860
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Dapagliflozin in patients with ...... phase IIb/III clinical trials.
@en
Dapagliflozin in patients with ...... phase IIb/III clinical trials.
@nl
type
label
Dapagliflozin in patients with ...... phase IIb/III clinical trials.
@en
Dapagliflozin in patients with ...... phase IIb/III clinical trials.
@nl
prefLabel
Dapagliflozin in patients with ...... phase IIb/III clinical trials.
@en
Dapagliflozin in patients with ...... phase IIb/III clinical trials.
@nl
P2093
P2860
P31
P50
P921
P356
P1476
Dapagliflozin in patients with ...... phase IIb/III clinical trials.
@en
P2093
Anna M Langkilde
Cathrina Karup
Jochen Seufert
P2860
P304
P356
10.1111/DOM.13124
P5008
P577
2017-10-26T00:00:00Z
2018-03-01T00:00:00Z